Coya Therapeutics Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Arun Swaminathan

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	0.06%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	3.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Oct 29

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Oct 13

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Mar 26

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Feb 13

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Jan 13

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Sep 06

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

May 17

AMMINISTRATORE DELEGATO

Arun Swaminathan

no data

Mandato

Dr. Arun Swaminathan, Ph.D. is Chief Executive Officer of Coya Therapeutics, Inc. from November 1, 2024. Dr. Swaminathan was Chief Business Officer of Coya Therapeutics, Inc. from August 2024 to November 1...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Howard Berman	Executive Chair	4.8yrs	US$1.32m	5.68% $ 6.1m
Fred Grossman	President & Chief Medical Officer	1.3yrs	US$862.61k	0.016% $ 17.3k
David Snyder	CFO & COO	2.7yrs	US$947.89k	0.053% $ 56.1k
Arun Swaminathan	Chief Executive Officer	no data	Nessun dato	0.060% $ 63.8k
Gregory MacMichael	Chief Technical Officer	3yrs	Nessun dato	Nessun dato
Michelle Frazier	Senior Vice President of Regulatory Affairs	1.4yrs	Nessun dato	Nessun dato
Aaron Thome	Head of Neuroinflammation Platform	no data	Nessun dato	Nessun dato
Karen King	Senior VP of Program Management & Clinical Operations	less than a year	Nessun dato	Nessun dato

1.3yrs

Durata media

63yo

Età media

Gestione esperta: Il team dirigenziale di COYA non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Howard Berman	Executive Chair	4.8yrs	US$1.32m	5.68% $ 6.1m
Dov Goldstein	Independent Director	3.7yrs	US$63.75k	0.060% $ 63.8k
Wilbur Ross	Independent Director	less than a year	Nessun dato	0.99% $ 1.1m
Stanley Appel	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Lawrence Steinman	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Malcolm Brenner	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ann Lee	Independent Director	3.4yrs	US$52.50k	0.13% $ 143.4k
Merit Cudkowicz	Clinical Advisor	1.3yrs	Nessun dato	Nessun dato
Dieter Weinand	Independent Director	1.3yrs	US$44.16k	Nessun dato
Anabella Villalobos	Independent Director	3.5yrs	US$53.75k	0.060% $ 63.8k
Shimon Sakaguchi	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Clive Svendsen	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

3.4yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di COYA sono considerati esperti (durata media dell'incarico 3.4 anni).

Coya Therapeutics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Coya Therapeutics, Inc. Announces CEO Changes, Effective November 1, 2024

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Wilbur Ross Joins Coya Therapeutics' Board

Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of Directors

Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor

Coya Therapeutics, Inc. Announces Management Changes, Effective July 17, 2023

Recent updates

New minor risk - Market cap size

Consensus revenue estimates decrease by 27%, EPS upgraded

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Coya Therapeutics, Inc. announced that it expects to receive $10.000027 million in funding

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Consensus EPS estimates fall by 10%

New minor risk - Share price stability

Coya Therapeutics, Inc. Announces CEO Changes, Effective November 1, 2024

Consensus revenue estimates fall by 24%

Coya Therapeutics, Inc. Submits an Investigational New Drug Application

Consensus revenue estimates fall by 44%

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

New major risk - Shareholder dilution

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

Consensus revenue estimates increase by 64%, EPS downgraded

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Consensus revenue estimates increase by 100%

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral Sclerosis

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Wilbur Ross Joins Coya Therapeutics' Board

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis

New minor risk - Share price stability

Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting

Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Coya Therapeutics, Inc. Reports the Publication of a Research Article Entitled “Immunological, Oxidative, and Structural Factors and Their Responses T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis”

Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of Directors

New major risk - Financial position

Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor

Coya Therapeutics Reports Additional Proof-Of-Concept Clinical Biomarker Data in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. Announces Management Changes, Effective July 17, 2023

Coya Therapeutics, Inc. to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Appoints Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs

Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD)

Coya Therapeutics, Inc. Announces Appointment of Dr. Guillaume Dorothée to Scientific Advisory Board

Coya Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Coya Therapeutics, Inc. Reports Results from an Open-Label Proof-Of-Concept Clinical Study for COYA 301 in patients with AD. Results of the study

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. has completed an IPO.

High number of new and inexperienced directors

Coya Therapeutics, Inc. has completed an IPO.

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media